| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tibor Stark, Jana Ruda-Kucerova, Fabio Arturo Iannotti, Claudio D'Addario, Roberta Di Marco, Vladimir Pekarik, Eva Drazanova, Fabiana Piscitelli, Monica Bari, Zuzana Babinska, Giovanni Giurdanella, Martina Di Bartolomeo, Salvatore Salomone, Alexandra Sulcova, Mauro Maccarrone, Carsten T Wotjak, Zenon Starcuk, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Mical. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology. vol 146. 2020-01-23. PMID:30496751. |
peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the mam model of schizophrenia. |
2020-01-23 |
2023-08-13 |
rat |
| Christian Makiol, Michael Klug. Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol. The Australian and New Zealand journal of psychiatry. vol 53. issue 3. 2019-12-31. PMID:30543310. |
remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol. |
2019-12-31 |
2023-08-13 |
Not clear |
| Michael L Miller, Benjamin Chadwick, Dara L Dickstein, Immanuel Purushothaman, Gabor Egervari, Tanni Rahman, Chloe Tessereau, Patrick R Hof, Panos Roussos, Li Shen, Mark G Baxter, Yasmin L Hur. Adolescent exposure to Δ Molecular psychiatry. vol 24. issue 4. 2019-12-03. PMID:30283037. |
the pfc undergoes significant maturation during adolescence, a period when cannabis use in humans has been linked to subsequent vulnerability to psychiatric disorders such as addiction and schizophrenia. |
2019-12-03 |
2023-08-13 |
rat |
| Leo E. Holliste. Health aspects of cannabis: revisited. The international journal of neuropsychopharmacology. vol 1. issue 1. 2019-11-20. PMID:11281947. |
although cannabis does not produce a specific psychosis, the possibility exists that it may exacerbate schizophrenia in persons predisposed to that disorder. |
2019-11-20 |
2023-08-12 |
Not clear |
| Mary F Brunette, Ree Dawson, Christopher D O'Keefe, Meera Narasimhan, Douglas L Noordsy, Joanne Wojcik, Alan I Gree. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. Journal of dual diagnosis. vol 7. issue 1-2. 2019-11-20. PMID:25914610. |
a randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Mary F Brunette, Ree Dawson, Christopher D O'Keefe, Meera Narasimhan, Douglas L Noordsy, Joanne Wojcik, Alan I Gree. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. Journal of dual diagnosis. vol 7. issue 1-2. 2019-11-20. PMID:25914610. |
cannabis use disorder is the most common co-occurring drug use disorder in people with schizophrenia and is associated with poor outcomes. |
2019-11-20 |
2023-08-13 |
Not clear |
| Mary F Brunette, Ree Dawson, Christopher D O'Keefe, Meera Narasimhan, Douglas L Noordsy, Joanne Wojcik, Alan I Gree. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. Journal of dual diagnosis. vol 7. issue 1-2. 2019-11-20. PMID:25914610. |
we launched a randomized controlled trial to assess the impact of clozapine compared with treatment as usual on cannabis use in patients with schizophrenia and co-occurring cannabis use disorder. |
2019-11-20 |
2023-08-13 |
Not clear |
| Ladislav Hosák, Jirina Hosakov. The complex etiology of schizophrenia - general state of the art. Neuro endocrinology letters. vol 36. issue 7. 2019-11-20. PMID:26859583. |
psychosocial stress and cannabis abuse seem to be the most important environmental factors in schizophrenia etiology. |
2019-11-20 |
2023-08-13 |
Not clear |
| Ladislav Hosák, Jirina Hosakov. The complex etiology of schizophrenia - general state of the art. Neuro endocrinology letters. vol 36. issue 7. 2019-11-20. PMID:26859583. |
postnatal risk factors (e.g., stress, urbanicity, cannabis use) may also affect the risk of schizophrenia via the potentiation of vulnerable brain pathways. |
2019-11-20 |
2023-08-13 |
Not clear |
| Karin J H Verweij, Abdel Abdellaoui, Michel G Nivard, Alberto Sainz Cort, Lannie Ligthart, Harmen H M Draisma, Camelia C Minică, Nathan A Gillespie, Gonneke Willemsen, Jouke-Jan Hottenga, Dorret I Boomsma, Jacqueline M Vin. Erratum to "Short communication: Genetic association between schizophrenia and cannabis use" [Drug Alcohol Depend. 171 (2017) 117-121]. Drug and alcohol dependence. vol 173. 2019-11-20. PMID:28283211. |
erratum to "short communication: genetic association between schizophrenia and cannabis use" [drug alcohol depend. |
2019-11-20 |
2023-08-13 |
Not clear |
| Kim R De Sousa, Arun K Tiwari, Daniel E Giuffra, Bronwyn Mackenzie, Clement C Zai, James L Kenned. Corrigendum to "Age at onset of schizophrenia: Cannabis, COMT gene, and their interactions" [Volume 151, Issues 1-3, December 2013, Pages 289-290]. Schizophrenia research. vol 169. issue 1-3. 2019-11-20. PMID:28760562. |
corrigendum to "age at onset of schizophrenia: cannabis, comt gene, and their interactions" [volume 151, issues 1-3, december 2013, pages 289-290]. |
2019-11-20 |
2023-08-13 |
Not clear |
| C Shahzade, J Chun, L E DeLisi, T C Manschrec. Patterns in adolescent cannabis use predict the onset and symptom structure of schizophrenia-spectrum disorder. Schizophrenia research. vol 197. 2019-11-08. PMID:29402581. |
participants (n = 178) were recruited for two samples, 1: healthy controls (hc) with cannabis use, 2: schizophrenia patients (ssd) with cannabis use. |
2019-11-08 |
2023-08-13 |
human |
| Seon-Cheol Park, Hong Seok Oh, Adarsh Tripathi, Roy Abraham Kallivayalil, Ajit Avasthi, Sandeep Grover, Andi Jayalangkara Tanra, Shigenobu Kanba, Takahiro A Kato, Toshiya Inada, Kok Yoon Chee, Mian-Yoon Chong, Shih-Ku Lin, Kang Sim, Yu-Tao Xiang, Chay Hoon Tan, Afzal Javed, Norman Sartorius, Naotaka Shinfuku, Yong Chon Par. Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia. Nordic journal of psychiatry. vol 73. issue 6. 2019-10-08. PMID:31240984. |
cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in asian patients with schizophrenia. |
2019-10-08 |
2023-08-13 |
Not clear |
| Marta Bosia, Mariachiara Buonocore, Margherita Bechi, Liliana-Mihaela Stere, Maria Paola Silvestri, Emanuela Inguscio, Marco Spangaro, Federica Cocchi, Laura Bianchi, Carmelo Guglielmino, Roberto Cavallar. Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. Progress in neuro-psychopharmacology & biological psychiatry. vol 92. 2019-09-24. PMID:30790675. |
based on these premises, the present study, aimed to analyze the interplay between cannabis use and comt polymorphism on cognitive performance in a sample of 135 patients with chronic schizophrenia. |
2019-09-24 |
2023-08-13 |
human |
| Leticia García Álvarez, Jesus J Gomar, Mª Paz García-Portilla, Julio Bobe. Cannabis use and cognitive impairment in schizophrenia and first-episode psychosis. Adicciones. vol 31. issue 2. 2019-09-09. PMID:31017245. |
cannabis use and cognitive impairment in schizophrenia and first-episode psychosis. |
2019-09-09 |
2023-08-13 |
Not clear |
| Maya R Jacobson, Jeremy J Watts, Isabelle Boileau, Junchao Tong, Romina Mizrah. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 3. 2019-08-26. PMID:30635160. |
the most well established finding is the down-regulation of cannabinoid cb1 receptors (cb1r) after chronic and recent cannabis exposure, but it remains uncertain whether this effect is present in cannabis users with schizophrenia. |
2019-08-26 |
2023-08-13 |
Not clear |
| William V Stoecker, Emily E Rapp, Joseph M Malter. Marijuana Use in the Era of Changing Cannabis Laws: What Are the Risks? Who is Most at Risk? Missouri medicine. vol 115. issue 5. 2019-08-21. PMID:30385981. |
disruption of the default mode network areas has been documented in schizophrenia and alzheimer's disease, illnesses with symptoms and brain changes that parallel findings in marijuana abusers. |
2019-08-21 |
2023-08-13 |
Not clear |
| Margaret Quinn, Maureen McHugo, Kristan Armstrong, Neil Woodward, Jennifer Blackford, Stephan Hecker. Impact of substance use disorder on gray matter volume in schizophrenia. Psychiatry research. Neuroimaging. vol 280. 2019-07-09. PMID:30121336. |
we used voxel-based morphometry (vbm) to examine whether differences in regional gray matter volumes exist between schizophrenia patients with (n = 92) and without (n = 66) clinically significant cannabis and/or alcohol use histories compared to 88 healthy control subjects. |
2019-07-09 |
2023-08-13 |
human |
| Margaret Quinn, Maureen McHugo, Kristan Armstrong, Neil Woodward, Jennifer Blackford, Stephan Hecker. Impact of substance use disorder on gray matter volume in schizophrenia. Psychiatry research. Neuroimaging. vol 280. 2019-07-09. PMID:30121336. |
within these regions, we found no volume differences between patients with schizophrenia and a history of cannabis and/or alcohol compared to patients with schizophrenia without a clinically significant substance use history. |
2019-07-09 |
2023-08-13 |
human |
| Margaret Quinn, Maureen McHugo, Kristan Armstrong, Neil Woodward, Jennifer Blackford, Stephan Hecker. Impact of substance use disorder on gray matter volume in schizophrenia. Psychiatry research. Neuroimaging. vol 280. 2019-07-09. PMID:30121336. |
our data support the idea that a clinically meaningful history of alcohol or cannabis use does not significantly compound the gray matter deficits associated with schizophrenia. |
2019-07-09 |
2023-08-13 |
human |